WO1992016494A1 - Long chain antiviral compounds - Google Patents
Long chain antiviral compounds Download PDFInfo
- Publication number
- WO1992016494A1 WO1992016494A1 PCT/GB1992/000438 GB9200438W WO9216494A1 WO 1992016494 A1 WO1992016494 A1 WO 1992016494A1 GB 9200438 W GB9200438 W GB 9200438W WO 9216494 A1 WO9216494 A1 WO 9216494A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- methyl
- compound according
- chain
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C211/14—Amines containing amino groups bound to at least two aminoalkyl groups, e.g. diethylenetriamines
Definitions
- This invention concerns improvements in chemical compounds, more especially it concerns compounds and pharmaceutical compositions. In particular it concerns compositions and compounds having activity in in vitro tests on Human Immunodeficiency Virus-infected cells.
- AIDS Acquired Immune Deficiency Syndrome
- chemo-therapeutic treatments have been advocated, and some compounds have emerged as a potential basis for treatment, there is still a need for alternatives.
- most treatments such as the compound known as AZT have a high toxicity to cells, and it would be desirable to find compounds which are less toxic. In man, the development of resistance to AZT has been identified as an additional clinical problem.
- the present invention provides the use of compounds defined below, in pharmaceutical compositions for treating HIV-infected patients.
- the invention further provides pharmaceutical compositions comprising a said compound in combination or association with a pharmaceutically acceptable diluent or carrier, for the treatment of HIV-infected patients.
- the invention may also be defined as the use of a said compound for the manufacture of a medicament for the treatment of HIV-infected patients.
- the invention further provides a process for the production of a pharmaceutical composition for the treatment of a HIV-infected patient, comprising the combination of a compound as defined below with a pharmaceutically acceptable diluent or carrier, and formulating said composition into a form suitable for administration to said patient.
- the invention also provides a method of treatment of an HIV-infected patient, comprising administering to said patient an effective dose of a said compound. It is to be understood that treatment includes prophylactic treatment of patients at risk, in view of the protective properties observed. Whilst this description is especially directed to combating HIV, this invention includes other aspects in which other diseases may be treated, including for example microbial infections.
- US Patent 4,156,683 discloses monocyclic and bicyclic macrocyclic compounds, which are said to have biological activity in regulating sodium, potassium and calcium levels in mammals. Additionally, a specific group of N-alkylated monocyclic compounds are said to possess activity against A 2 influenza viruses in a modified Hermann test on chick fibroblast tissue. The single example mentioned of such N-alkylates/ monocyclic compounds is 4, 13-dimethyl-l ,7, 10,16-tetra-4, 13-diazacyclo- octadecane. It is also said that the preferred compounds, which form complexes of greater stability, are those having three bridging chains between bridgehead nitrogen atoms, that is fused bicyclic compounds.
- the present invention provides active compounds of the general formula I, Z - (A) n - Y I in which each Z and Y is independently a poiyheteroalkyl chain having a chain length of 9 to 32 members or a polyheterocyclic moiety having from 9 to 32 ring members, and each having from 3 to 8 heteroatoms, wherein the heteroatoms are selected from nitrogen, oxygen and sulphur, provided that at least one of Z and Y is a said chain,
- A is a linking atom or group, and n is O or an integer from 1 to 6.
- A may be alkylene, for example 1 ,3 propandiyl, unsaturated alkylene or a group selected from aryl. alkylaryl. alkylarylalkyl, fused aryl. polyoxoethylene. carboxylate, esters and amides, or a nitrogen or sulphur atom. In a particularly preferred embodiment of the invention.
- A is alkylene of 1 to 6 carbon atoms or is alkylphenylalkyl in which each alkyl is of 1 to 6 carbon atoms and the phenyl ring is unsubstituted or substituted by methoxy, fluorine, chlorine, bromine or nitro, and the alkyl groups are in the m- or p- positions relative to one another.
- the chains or heterocycles Z and Y may be linked to the remainder of the molecule through carbon or heteroatoms, for example linked through C.C ,C,N' or N,N' .
- Each of Z and Y may contain nitrogen and/or oxygen and/or sulphur heteroatoms; preferably the moieties contain nitrogen atoms with optional further heteroatoms selected from oxygen and sulphur.
- a particular embodiment of the invention relates to compounds in which all the chain or nuclear heteroatoms are nitrogen atoms.
- a more preferred embodiment relates to compounds in which each of Z and Y contain four nitrogen atoms.
- the chains or cyclic moieties may be substituted or unsubstituted, and may contain unsaturation. Suitable substituents may be selected from halogens, especially fluorine, chlorine or bromine. -NH 2 . -OH. -COOH. ester groups, -CONH 2 and alkyl or aryl groups, eg of up to 10 carbon atoms, which themselves may be substituted by the aforementioned substituents.
- Preferred chains are of 8 to 18 atoms, especially 8 to 16 atoms, preferably with 4 to 8 nitrogen heteroatoms; preferred cyclic moieties are those of 10 to 24 ring members, especially 12 to 18 ring members, and preferred numbers of nuclear nitrogen atoms are 4 to 6. It is convenient that if two chains are linked, they are identical.
- the invention also includes what may be termed "pro-drugs", that is protected forms of the linked compounds, which release the compound after administration to a patient.
- the compound may carry a protective group which is split off by hydrolysis in body fluids, e.g. in the bloodstream, thus releasing active compound.
- a discussion of pro-drugs may be found in "Smith and Williams' Introduction to the Principles of Drug
- Ciampolini et al (Inorg Chem 26, 3527[1987]) have demonstrated the syntheses of alkyl-linked bicyclams by condensation of N.N' ,N"-tritosy ley clam with bis (tosyloxy)alkanes or with bis(acyl chlorides).
- C.N' - and N,N' -linked compounds of formula I may be performed in a similar manner by reacting activated precursors (eg compounds substituted with alkyl chains terminated with halides or activated carboxylates) with (N-l)-substituted heterocycles (eg N,N' ,N"-tritosylcyclam) or (N-l )-substituted polyazaalkanes followed by deprotection.
- activated precursors eg compounds substituted with alkyl chains terminated with halides or activated carboxylates
- heterocycles eg N,N' ,N"-tritosylcyclam
- the invention further provides a process for the production of compounds of formula I. comprising reacting a compound of formula II or III, Z - (A) n - X 1 II
- X 1 is a reactive atom or group with a compound of formula IV or V, respectively,
- X 2 is a reactive atom or group, under conditions such that a compound of formula I is formed and the reactive atoms or groups X 1 and X 2 are split off. It will be realised that it may be desirable to protect other reactive sites on the moieties Z and Y, for example amino nitrogen atoms, from participation in unwanted reactions, and this may be done by methods well known to the skilled synthetic chemist, followed by deprotection. Such process variants are to be understood as being within the scope of the invention.
- the compounds are indicated for the treatment of viral infections, especially retrovirus infections and particularly HIV infections, and the compounds of formula I, are to be be considered as active compounds for the pharmaceutical compositions, processes for making the same and methods of treatment mentioned above.
- meso forms, enantiomers and resolved optically active forms of the compounds of formula I. are included.
- compounds of formula I diluted with non-toxic or with other active substances include Acid addition salts, for example hydrochlorides, and non-toxic labile metal complexes of the compounds of formula I are also active compounds according to the present invention.
- Non-toxic in the present context has to be considered with reference to the prognosis for the infected patient without treatment.
- Zinc and nickel complexes are especially indicated, whereas less labile metal atoms such as cobalt and rhodium are less preferred because of likely lower selectivity.
- the tetraamine was synthesised from meso-erythritol according to the method of R L Weller, J Org Chem 49, 5150 (1984).
- N-tosyl-3-aminopropanoate (8 equivalents) in dimethylformamide.
- the reaction mixture was heated at 50° C for 5days.
- the DMF was removed under reduced pressure and dissolved in THF/1N NaOH and stirred overnight during which time a white/yellow solid precipitated which was removed by filtration.
- the solid was dissolved in dichloromethane and triethylamine (6 equivalents) was added. To the homogeous solution a solution of mesyl chloride (4.5 equivalent) in dichloromethane was added dropwise and the reaction mixture was stirred overnight at room temperature. Dichloromethane and water were added and the phases were separated. The organic phase was washed with 10% HCl and brine, dried over magnesium sulphate and concentrated to give a white amorphous solid. The solid was dissolved in ethyl acetate and passed through a column of silica gel using ethyl acetate as eluant. The eluate was concentrated to dryness to give the desired product as an amorphous solid; overall yield 30%; mass spectrum 1275 (14%), 1197 (100%), 559 (13%).
- step c) The mixture produced in step b) (420mg, 0.448mmol) was added to 12ml of acetic acid and 6ml of 48%aq HBr (Aldrich) and the solution was stirred for 30 hours at 110-120°C. The red solution was cooled to room temperature and concentrated to a paste. Acetic acid (10ml) was added and the resulting solid was collected by filtration through a sintered glass funnel. The tan-white solid was washed with acetic acid (20ml) and ether (20ml) and dried under vacuum overnight (60°C/0.4mm Hg). A tan- white solid was thus obtained (400mg.
- step b) The product from step a) above (220mg. 0.242mmol) was added to 8ml of acetic acid and 6ml of 48% aq HBr (Aldrich) and the solution was stirred for 30 hours at 110-120° C. The red solution was cooled to room temperature and concentrated to a paste. Acetic acid (lOml) was added and the resulting solid was collected by filtration through a sintered glass funnel. The solid was washed with acetic acid (20ml) and ether (30ml) and dried under vacuum overnight (60°C/0.4mm Hg).
- a tan-white solid was thus obtained (120mg, 46%) as an approximate 2: 1 mixture of 1 -(l-( 1 ,4, 7, 10- tetraazadecyl)methyl)-4-( 1 -( 1 ,4,8, 1 1 -tetraazacyclotetradecyl)methyl)benzene octahydrobromide and 1-(1-(1,4,8.1 l-tetraazacyclotetradecyl)methyI)-4-(4- (1.4,7.10-tetraazadecyl)methyl)benzene.
- the products were separated using chromatography, and their structures were confirmed.
- step b) 80mg (0.051mmol) of the product of step a) above was added to 6ml acetic acid and 4ml of 48% aq HBr (Aldrich) and the solution was stirred for 48 hours at 1 10-120°C. The brown solution was cooled to room temperature and concentrated to a paste. Acetic acid (8ml) was added and the resulting solid was collected by filtration through a sintered glass funnel. The solid was washed with acetic acid (10ml) and ether (10ml) and dried under vacuum overnight (60°C/0.4mm Hg).
- the compound of the invention was tested in a screen by the MTT method (J.Virol. Methods 120: 309-321 [1988]).
- MT-4 cells 2.5 x 10 4 / well
- HIV-1 HIV-1
- LAV-2 ROD HIV-2
- Antiviral activity and cytotoxicity of the compounds are expressed in the table below as ED 50 (ug/ml) and CD 50 (ug/ml), respectively.
- the potential therapeutic usefulness was assessed by calculating a Selectivity Index (SI) corresponding to the ratio of CD 50 to ED 50 .
- SI Selectivity Index
- any compound exhibiting a Selectivity Index of greater than 5 has the potential for further study.
- HIV is one of the most challenging viruses to combat, and the results given above provide an indication of activity against other retroviruses and against other viruses in general.
- the compounds of the invention are also to be considered for activity against microorganisms, such as bacteria and especially against the organisms causing malaria.
- the active compounds may be administered in the form of pharmaceutical compositions formulated according to well known principles and incorporated the compound, preferably in unit dose form, in combination with a pharmaceutically acceptable diluent or excipient.
- Such compositions may be in the form of solutions or suspensions for injection, or irrigation or be in capsule, tablet, dragee, or other solid composition or as a solution or suspension for oral administration or formulated into pessaries or suppositories or sustained release forms of any of the above for implantation.
- Suitable diluents, carriers, excipients and other components are known. It may be desirable also to formulate a composition for topical administration such as an ointment or cream.
- the compounds of the invention may be used, in the form of a composition or alone, and possibly carried on a finely divided form of a composition or alone, and possibly carried on a finely divided support, as a coating on devices which in use contact body fluids, to discourage transmission of viral infections.
- devices to be considered in this aspect of the invention are surgical devices and gloves and contraceptions such as condoms, and other items, appliances, wound dressings and coverings, implements etc generally to be considered as devices according to this aspect of the invention.
- compositions according to the invention may contain unit dosages determined in accordance with conventional pharmacological methods, suitably to provide active compounds in the dosage range in humans of from 0.1 to 100 mg/kg body weight per day, in a single dose or in a number of smaller doses. Preferred dosage ranges are 1 to 30 mg/kg body weight per day. Other active compounds may be used in the compositions or such active compounds or supplemental therapy may be included in a course of treatment.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4506034A JPH06505728A (ja) | 1991-03-15 | 1992-03-11 | 長鎖の抗ウィルス化合物 |
FI933828A FI933828A0 (fi) | 1991-03-15 | 1993-09-01 | Laongkedjade antivirala foereningar |
NO93933273A NO933273L (no) | 1991-03-15 | 1993-09-14 | Langkjedete anti-virusforbindelser |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB919105489A GB9105489D0 (en) | 1991-03-15 | 1991-03-15 | Improvements in chemical compounds |
GB9105489.0 | 1991-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1992016494A1 true WO1992016494A1 (en) | 1992-10-01 |
Family
ID=10691614
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1992/000438 WO1992016494A1 (en) | 1991-03-15 | 1992-03-11 | Long chain antiviral compounds |
Country Status (8)
Country | Link |
---|---|
JP (1) | JPH06505728A (no) |
AU (1) | AU1372092A (no) |
CA (1) | CA2106068A1 (no) |
FI (1) | FI933828A0 (no) |
GB (1) | GB9105489D0 (no) |
HU (1) | HU9302596D0 (no) |
NO (1) | NO933273L (no) |
WO (1) | WO1992016494A1 (no) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993012096A1 (en) * | 1991-12-16 | 1993-06-24 | Johnson Matthey Public Limited Company | Linked cyclic polyamines with activity against hiv |
WO1995007270A1 (en) * | 1993-09-07 | 1995-03-16 | Nycomed Salutar, Inc. | Chelants as contrast enhancing agents |
WO1996034860A1 (en) * | 1995-05-02 | 1996-11-07 | Johnson Matthey Plc | Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane |
EP0747368A1 (en) * | 1995-06-06 | 1996-12-11 | Johnson Matthey Public Limited Company | Derivatives of monocyclic polyamines, their preparation, and their use as antiviral agents |
WO2000002870A1 (en) * | 1998-07-08 | 2000-01-20 | Anormed Inc. | Antiviral macrocyclic compounds |
WO2000021941A1 (en) * | 1998-10-13 | 2000-04-20 | Synchem Reserach, Inc. | Biomimetic chelating agents and methods |
EP1189609A1 (en) * | 1999-05-03 | 2002-03-27 | Smithkline Beecham Corporation | Cxcr-4 receptor antagonists - thrombopoietin mimetics |
US6667320B2 (en) | 1999-12-17 | 2003-12-23 | Anormed | Chemokine receptor binding heterocyclic compounds |
WO2007022523A2 (en) | 2005-08-19 | 2007-02-22 | Genzyme Corporation | Methods to enhance chemotherapy |
US7897590B2 (en) | 2001-07-31 | 2011-03-01 | Genzyme Corporation | Methods to mobilize progenitor/stem cells |
WO2012158707A1 (en) | 2011-05-16 | 2012-11-22 | Genzyme Corporation | Use of cxcr4 antagonists |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4156683A (en) * | 1973-03-26 | 1979-05-29 | Schering Corporation | Complexes of macrocyclic compounds |
EP0270349A2 (en) * | 1986-12-02 | 1988-06-08 | The University Of Florida | Use of an anti-neoplastic spermine derivative in the preparation of a pharmaceutical composition |
EP0296522A2 (en) * | 1987-06-24 | 1988-12-28 | The Dow Chemical Company | Functionalized polyamine chelants and rhodium complexes thereof and process for their preparation |
EP0305320A2 (de) * | 1987-08-24 | 1989-03-01 | Schering Aktiengesellschaft | Mehrkernige substituierte Komplexbildner, Komplexe und Komplexsalze, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Mittel |
EP0349224A2 (en) * | 1988-06-23 | 1990-01-03 | The University Of Florida | Anti-neoplastic, anti-viral or anti-retroviral spermine derivatives |
EP0378146A2 (en) * | 1989-01-10 | 1990-07-18 | Merrell Pharmaceuticals Inc. | Polyamine derivatives as antineoplastic agents |
WO1991005762A1 (en) * | 1989-10-23 | 1991-05-02 | Cockbain, Julian, Roderick, Michaelson | Multi-site metal chelating agents |
US5021409A (en) * | 1989-12-21 | 1991-06-04 | Johnson Matthey Plc | Antiviral cyclic polyamines |
-
1991
- 1991-03-15 GB GB919105489A patent/GB9105489D0/en active Pending
-
1992
- 1992-03-11 AU AU13720/92A patent/AU1372092A/en not_active Abandoned
- 1992-03-11 WO PCT/GB1992/000438 patent/WO1992016494A1/en active Application Filing
- 1992-03-11 CA CA002106068A patent/CA2106068A1/en not_active Abandoned
- 1992-03-11 HU HU9302596A patent/HU9302596D0/hu unknown
- 1992-03-11 JP JP4506034A patent/JPH06505728A/ja active Pending
-
1993
- 1993-09-01 FI FI933828A patent/FI933828A0/fi not_active Application Discontinuation
- 1993-09-14 NO NO93933273A patent/NO933273L/no unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4156683A (en) * | 1973-03-26 | 1979-05-29 | Schering Corporation | Complexes of macrocyclic compounds |
EP0270349A2 (en) * | 1986-12-02 | 1988-06-08 | The University Of Florida | Use of an anti-neoplastic spermine derivative in the preparation of a pharmaceutical composition |
EP0296522A2 (en) * | 1987-06-24 | 1988-12-28 | The Dow Chemical Company | Functionalized polyamine chelants and rhodium complexes thereof and process for their preparation |
EP0305320A2 (de) * | 1987-08-24 | 1989-03-01 | Schering Aktiengesellschaft | Mehrkernige substituierte Komplexbildner, Komplexe und Komplexsalze, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Mittel |
EP0349224A2 (en) * | 1988-06-23 | 1990-01-03 | The University Of Florida | Anti-neoplastic, anti-viral or anti-retroviral spermine derivatives |
EP0378146A2 (en) * | 1989-01-10 | 1990-07-18 | Merrell Pharmaceuticals Inc. | Polyamine derivatives as antineoplastic agents |
WO1991005762A1 (en) * | 1989-10-23 | 1991-05-02 | Cockbain, Julian, Roderick, Michaelson | Multi-site metal chelating agents |
US5021409A (en) * | 1989-12-21 | 1991-06-04 | Johnson Matthey Plc | Antiviral cyclic polyamines |
Non-Patent Citations (2)
Title |
---|
CHEMICAL ABSTRACTS, vol. 88, no. 15, 10 April 1978, Columbus, Ohio, US; abstract no. 105292S, ZIMENKOVSKII, B.S.: 'Synthesis and properties of tetraazamacrosanes and their derivatives.' page 570 ;column 1 ; cited in the application * |
JOURNAL OF MEDICINAL CHEMISTRY vol. 34, no. 2, February 1991, U.S.A. pages 569 - 574; M.L. EDWARDS: 'Antimalarial Polyamine Analogues.' cited in the application * |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993012096A1 (en) * | 1991-12-16 | 1993-06-24 | Johnson Matthey Public Limited Company | Linked cyclic polyamines with activity against hiv |
US5583131A (en) * | 1991-12-16 | 1996-12-10 | Johnson Matthey Public Limited Company | Aromatic-linked polyamine macrocyclic compounds with anti-HIV activity |
USRE42152E1 (en) | 1991-12-16 | 2011-02-15 | Genzyme Corporation | Aromatic-linked polyamine macrocyclic compounds with anti-HIV activity |
EP1223166A1 (en) * | 1991-12-16 | 2002-07-17 | AnorMED Inc. | Linked cyclic polyamines with activity against hiv. |
WO1995007270A1 (en) * | 1993-09-07 | 1995-03-16 | Nycomed Salutar, Inc. | Chelants as contrast enhancing agents |
US5958373A (en) * | 1993-09-07 | 1999-09-28 | Nycomed Salutar Inc. | Polychelants as contrast enhancing agents |
WO1996034860A1 (en) * | 1995-05-02 | 1996-11-07 | Johnson Matthey Plc | Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane |
EP0747368A1 (en) * | 1995-06-06 | 1996-12-11 | Johnson Matthey Public Limited Company | Derivatives of monocyclic polyamines, their preparation, and their use as antiviral agents |
US5817807A (en) * | 1995-06-06 | 1998-10-06 | Anormed Inc. | Antiviral compounds |
US6756391B2 (en) | 1995-06-06 | 2004-06-29 | Anormed, Inc. | Antiviral compounds |
KR100420725B1 (ko) * | 1995-06-06 | 2004-06-12 | 아노메드 인코포레이티드 | 개선된항바이러스화합물 |
US6506770B1 (en) | 1996-06-06 | 2003-01-14 | Anormed, Inc. | Antiviral compounds |
US7160872B2 (en) | 1996-06-06 | 2007-01-09 | Anormed Inc. | Methods to treat conditions mediated by chemokine receptors |
WO2000002870A1 (en) * | 1998-07-08 | 2000-01-20 | Anormed Inc. | Antiviral macrocyclic compounds |
US7709486B2 (en) | 1998-07-08 | 2010-05-04 | Genzyme Corporation | CXCR4 antagonists |
US7414065B2 (en) | 1998-07-08 | 2008-08-19 | Genzyme Corporation | Methods to modulate conditions mediated by the CXCR4 receptor |
US6872714B1 (en) | 1998-07-08 | 2005-03-29 | Anormed Inc. | Methods to modulate conditions mediated by the CXCR4 receptor |
AP1436A (en) * | 1998-07-08 | 2005-06-22 | Anormed Inc | Antiviral macrocyclic compounds. |
WO2000021941A1 (en) * | 1998-10-13 | 2000-04-20 | Synchem Reserach, Inc. | Biomimetic chelating agents and methods |
EP1189609A4 (en) * | 1999-05-03 | 2002-10-30 | Smithkline Beecham Corp | CXCR-4 RECEPTOR ANTAGONISTS AND THROMBOPOIETIN MIMETIKA |
EP1189609A1 (en) * | 1999-05-03 | 2002-03-27 | Smithkline Beecham Corporation | Cxcr-4 receptor antagonists - thrombopoietin mimetics |
US7022717B2 (en) | 1999-12-17 | 2006-04-04 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds |
US6667320B2 (en) | 1999-12-17 | 2003-12-23 | Anormed | Chemokine receptor binding heterocyclic compounds |
US7897590B2 (en) | 2001-07-31 | 2011-03-01 | Genzyme Corporation | Methods to mobilize progenitor/stem cells |
WO2007022523A2 (en) | 2005-08-19 | 2007-02-22 | Genzyme Corporation | Methods to enhance chemotherapy |
WO2012158707A1 (en) | 2011-05-16 | 2012-11-22 | Genzyme Corporation | Use of cxcr4 antagonists |
Also Published As
Publication number | Publication date |
---|---|
NO933273D0 (no) | 1993-09-14 |
CA2106068A1 (en) | 1992-09-16 |
FI933828A (fi) | 1993-09-01 |
AU1372092A (en) | 1992-10-21 |
GB9105489D0 (en) | 1991-05-01 |
JPH06505728A (ja) | 1994-06-30 |
NO933273L (no) | 1993-09-14 |
FI933828A0 (fi) | 1993-09-01 |
HU9302596D0 (en) | 1993-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2032261C (en) | Antiviral polyheterocyclic dimers | |
US6001826A (en) | Chemical compounds | |
KR100420725B1 (ko) | 개선된항바이러스화합물 | |
USRE42152E1 (en) | Aromatic-linked polyamine macrocyclic compounds with anti-HIV activity | |
WO2008116385A1 (en) | Caffeoyl quinic acid derivatives containing nitrogen, and preparation method, pharmaceutically composition and usage thereof | |
WO1992016494A1 (en) | Long chain antiviral compounds | |
JPH0780842B2 (ja) | デイスタマイシン誘導体およびそれらの製造方法 | |
EP0350012A2 (en) | Antiviral composition | |
KR880000786B1 (ko) | 피페라진 유도체의 제조방법 | |
JPH11500130A (ja) | 抗ウイルス性トリアザ化合物 | |
EP0350878A2 (en) | Conjugated gamma-oxybutenolide compounds for treating ulcer | |
JPWO2004103360A1 (ja) | 抗ウイルス作用を有する化合物およびその配合剤 | |
US4812472A (en) | Isoxazole compounds and pharmaceutical compositions containing them for treatment and prophylaxis of retroviruses diseases | |
GB2065111A (en) | Decaprenylamine derivatives | |
WO2004080453A1 (ja) | 抗c型肝炎ウイルス剤と抗hiv剤 | |
KR100469778B1 (ko) | 디스타마이신유도체,이의제조방법,및항종양성및항바이러스성제제로서의이들의용도 | |
GB2076395A (en) | Nonaprenylamine derivatives | |
WO1993015607A1 (en) | Ion pairs of hypericin compounds having antiviral activity | |
CA1150268A (en) | Decaprenylamine derivatives | |
JPS6036463A (ja) | アラントイン誘導体 | |
EP0322822A2 (en) | Use of lactam containing compounds for the manufacture of an antiviral agent | |
GB2065109A (en) | Decaprenylamine derivatives | |
JPH05246862A (ja) | エイズウイルス増殖抑制剤 | |
JPS60178865A (ja) | ベンジルチオピペラジン誘導体その製造方法及び高血圧治療薬 | |
JPS6253964A (ja) | 脂環式ジカルボン酸イミド化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA FI HU JP KR NO US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 933828 Country of ref document: FI |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2106068 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 1993 119098 Country of ref document: US Date of ref document: 19930915 Kind code of ref document: A |
|
122 | Ep: pct application non-entry in european phase | ||
122 | Ep: pct application non-entry in european phase |